HDIM
TEVA icon

Hanson & Doremus Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Hanson & Doremus Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,571
Closed -$34K – 540
2022
Q1 		$34K Sell
3,571
-1,035
-22% -$8.64K 0.01% 351
2021
Q4 		$37K Hold
4,606
– – 0.01% 330
2021
Q3 		$45K Sell
4,606
-13,836
-75% -$130K 0.01% 305
2021
Q2 		$166K Buy
18,442
+3,595
+24% +$38.1K 0.05% 175
2021
Q1 		$171K Sell
14,847
-250
-2% -$2.87K 0.04% 193
2020
Q4 		$146K Sell
15,097
-3,345
-18% -$32K 0.04% 200
2020
Q3 		$166K Sell
18,442
-310
-2% -$3.28K 0.05% 175
2020
Q2 		$231K Sell
18,752
-2,722
-13% -$30.8K 0.07% 144
2020
Q1 		$193K Sell
21,474
-262
-1% -$2.68K 0.07% 154
2019
Q4 		$213K Sell
21,736
-8,582
-28% -$76.6K 0.06% 168
2019
Q3 		$209K Sell
30,318
-11,481
-27% -$88K 0.07% 167
2019
Q2 		$386K Buy
41,799
+395
+1% +$4.76K 0.12% 119
2019
Q1 		$649K Sell
41,404
-2,672
-6% -$47.1K 0.21% 95
2018
Q4 		$680K Sell
44,076
-4,503
-9% -$92.3K 0.25% 90
2018
Q3 		$1.05M Buy
48,579
+277
+0.6% +$6.43K 0.33% 72
2018
Q2 		$1.18M Sell
48,302
-146
-0.3% -$2.98K 0.39% 68
2018
Q1 		$828K Buy
48,448
+3,358
+7% +$65.6K 0.26% 93
2017
Q4 		$854K Sell
45,090
-15,345
-25% -$231K 0.28% 88
2017
Q3 		$1.06M Buy
60,435
+907
+2% +$20.4K 0.37% 74
2017
Q2 		$1.98M Buy
59,528
+10,020
+20% +$310K 0.73% 32
2017
Q1 		$1.59M Buy
49,508
+10,135
+26% +$346K 0.64% 41
2016
Q4 		$1.43M Buy
39,373
+7,545
+24% +$301K 0.62% 45
2016
Q3 		$1.46M Buy
31,828
+4,412
+16% +$230K 0.68% 44
2016
Q2 		$1.38M Sell
27,416
-565
-2% -$30.1K 0.62% 45
2016
Q1 		$1.5M Sell
27,981
-485
-2% -$28.5K 0.68% 39
2015
Q4 		$1.87M Sell
28,466
-550
-2% -$34K 0.85% 32
2015
Q3 		$1.64M Sell
29,016
-1,090
-4% -$70.7K 0.79% 36
2015
Q2 		$1.78M Sell
30,106
-995
-3% -$61.4K 0.76% 39
2015
Q1 		$1.94M Sell
31,101
-525
-2% -$30.5K 0.82% 38
2014
Q4 		$1.82M Sell
31,626
-190
-0.6% -$10.6K 0.78% 37
2014
Q3 		$1.71M Hold
31,816
– – 0.77% 39
2014
Q2 		$1.67M Sell
31,816
-180
-0.6% -$9.2K 0.77% 40
2014
Q1 		$1.69M Buy
31,996
+815
+3% +$37.7K 0.8% 36
2013
Q4 		$1.25M Buy
31,181
+4,070
+15% +$160K 0.6% 52
2013
Q3 		$1.02M Buy
27,111
+4,575
+20% +$178K 0.52% 61
2013
Q2 		$883K Buy
+22,536
New +$878K 0.48% 65

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hanson & Doremus Investment Management's TEVA Position: Q2 2022 in Review

Hanson & Doremus Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2022, closing a stake of 3,571 shares — an estimated $34K sold.

Hanson & Doremus Investment Management first reported a position in TEVA in Q2 2013 and held it in 36 quarters. The position peaked at $1.98M in Q2 2017. 456 funds tracked by Wall St. Rank hold TEVA as of Q2 2022.

  • Hanson & Doremus Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Hanson & Doremus Investment Management sold 3,571 Teva Pharmaceuticals shares in Q2 2022, an estimated $34K.
  • Hanson & Doremus Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 36 quarters.
  • Hanson & Doremus Investment Management's Teva Pharmaceuticals position peaked at $1.98M in Q2 2017.
  • 456 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2022.

Based on Hanson & Doremus Investment Management's 13F filing for Q2 2022, filed 19 Jul 2022.